67O - Cabazitaxel (cbz) vs topotecan (tpt) in patients (pts) with small cell lung cancer (SCLC) with progressive disease during/after first-line (1l) trea...

Date 28 March 2014
Event ELCC 2014
Session Proffered papers 4 - SCLC and locally advanced NSCLC
Topics Anti-Cancer Agents & Biologic Therapy
Small-Cell Lung Cancer
Presenter Tracey Evans
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors T. Evans1, B.C. Cho2, K. Udud3, J.R. Fischer4, F.A. Shepherd5, P. Martinez6, R. Ramlau7, K.N. Syrigos8, M. Chadjaa9, M. Wolf10
  • 1Perelman Center For Advanced Medicine, University of Pennsylvania, PA 19104 - Philadelphia/US
  • 2Yonsei Cancer Center, Yonsei University Health System, Seoul/KP
  • 3N/a, Korányi National Institute of Pulmonology, Budapest/HU
  • 4N/a, Klinikum Loewenstein, Loewenstein/DE
  • 5N/a, Princess Margaret Cancer Centre, Toronto/CA
  • 6N/a, Vall d’Hebron University Hospital, Barcelona/ES
  • 7N/a, Poznan University of Medical Sciences, Poznan/PL
  • 8Oncology Unit, 3rd Department Of Medicine, Athens University School of Medicine, Sotiria General Hospital, Athens/GR
  • 9N/a, Sanofi, Vitry-sur-Seine/FR
  • 10Division Of Haematology And Oncology, Klinikum Kassel, Kassel/DE

 

Abstract

Platinum-based ctx is the 1L standard of care for SCLC, but despite high response rates, most SCLC pts experience rapid relapse and die from systemic metastases (mets). Therefore, more effective second-line (2L) treatments are needed. Taxanes are active 2L in SCLC, and Cbz is effective in 2L in other solid tumors. We compared Cbz vs Tpt in a randomized open-label Phase II trial in pts with SCLC who had progressed during/after 1L ctx (NCT01500720).